CA3184836A1 - Biomarkers related to kidney function and methods using the same - Google Patents
Biomarkers related to kidney function and methods using the sameInfo
- Publication number
- CA3184836A1 CA3184836A1 CA3184836A CA3184836A CA3184836A1 CA 3184836 A1 CA3184836 A1 CA 3184836A1 CA 3184836 A CA3184836 A CA 3184836A CA 3184836 A CA3184836 A CA 3184836A CA 3184836 A1 CA3184836 A1 CA 3184836A1
- Authority
- CA
- Canada
- Prior art keywords
- kidney function
- subject
- inositol
- creatinine
- myo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822965P | 2013-05-14 | 2013-05-14 | |
| US61/822,965 | 2013-05-14 | ||
| CA2911204A CA2911204C (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2911204A Division CA2911204C (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3184836A1 true CA3184836A1 (en) | 2014-11-20 |
Family
ID=51898805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3184836A Pending CA3184836A1 (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
| CA2911204A Active CA2911204C (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2911204A Active CA2911204C (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10539575B2 (enExample) |
| EP (3) | EP3410115A1 (enExample) |
| JP (1) | JP6595984B2 (enExample) |
| CN (2) | CN110196335A (enExample) |
| AU (1) | AU2014265669B2 (enExample) |
| BR (1) | BR112015028253A2 (enExample) |
| CA (2) | CA3184836A1 (enExample) |
| ES (2) | ES2871823T3 (enExample) |
| MX (2) | MX365061B (enExample) |
| WO (1) | WO2014186311A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3410115A1 (en) * | 2013-05-14 | 2018-12-05 | Metabolon, Inc. | Tryptophan as a biomarkers for kidney function and methods using the same |
| WO2015057968A2 (en) | 2013-10-17 | 2015-04-23 | The General Hospital Corporation | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
| HUE047951T2 (hu) * | 2015-01-09 | 2020-05-28 | Global Genomics Group Llc | Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására |
| US20180003721A1 (en) * | 2015-01-15 | 2018-01-04 | Joslin Diabetes Center | Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients |
| WO2017059132A1 (en) * | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
| US20170234874A1 (en) * | 2015-10-07 | 2017-08-17 | Clearbridge Biophotonics Pte Ltd. | Integrated visual morphology and cell protein expression using resonance-light scattering |
| US12057228B1 (en) * | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| US10865183B2 (en) | 2016-07-28 | 2020-12-15 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| EP3552022B1 (en) * | 2016-11-25 | 2021-06-09 | Implexion AB | Metabolic disorders |
| ES3004083T3 (en) * | 2016-12-19 | 2025-03-11 | Metabolon Inc | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| CN108956790A (zh) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用 |
| CN107132266A (zh) * | 2017-06-21 | 2017-09-05 | 佛山科学技术学院 | 一种基于随机森林的水质分类方法及系统 |
| AU2018313853A1 (en) | 2017-08-08 | 2020-01-02 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| CN107326093B (zh) * | 2017-09-04 | 2020-01-21 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| US11680042B2 (en) * | 2017-09-28 | 2023-06-20 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| CA3089817A1 (en) * | 2018-01-19 | 2019-07-25 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| JP7633147B2 (ja) * | 2018-07-14 | 2025-02-19 | マース インコーポレーテッド | 慢性腎臓病のためのバイオマーカー及びテストモデル |
| CN113454462A (zh) * | 2019-02-20 | 2021-09-28 | 株式会社合伙企业 | 固相反应芯片和使用该固相反应芯片的测定方法 |
| CN112305089B (zh) * | 2019-07-26 | 2022-04-29 | 长沙都正生物科技股份有限公司 | 一种慢性肾病诊断生物标记物及其应用 |
| CN114269722B (zh) * | 2019-07-26 | 2024-11-22 | 贝尔维奇生物医学研究所(伊迪贝尔) | 麦角硫因、s-甲基-麦角硫因及其用途 |
| CN111487338B (zh) * | 2020-04-16 | 2022-06-10 | 中南大学湘雅二医院 | 一种与肾功能相关的无创生物标记物及其应用 |
| CN114026427B (zh) * | 2020-05-19 | 2023-11-17 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| KR102697110B1 (ko) | 2020-12-07 | 2024-08-22 | 킴벌리-클라크 월드와이드, 인크. | 대사산물을 검출하기 위한 방법 및 소비자 제품 |
| AU2022426744A1 (en) * | 2021-12-27 | 2024-05-23 | Société des Produits Nestlé S.A. | Compositions and methods for diagnosing and treating chronic kidney disease |
| CN114910587B (zh) * | 2022-05-12 | 2024-03-19 | 军科正源(上海)生物医药科技有限公司 | 一种尿液检测用高效液相-串联质谱分析方法 |
| WO2026120352A1 (en) * | 2024-12-03 | 2026-06-11 | Societe Des Produits Nestle Sa | Estimating glomerular filtration rates in felines |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196787A (ja) | 1989-01-25 | 1990-08-03 | Otsuka Pharmaceut Co Ltd | シュードウリジン誘導体 |
| JPH0661278B2 (ja) | 1990-09-18 | 1994-08-17 | 旭化成工業株式会社 | ミオイノシトールの高感度定量法および定量用組成物 |
| US5712084A (en) * | 1995-09-08 | 1998-01-27 | Research Corporation Technologies, Inc. | Donor kidney viability test for improved preservation |
| CN101377492B (zh) | 2007-08-29 | 2014-04-23 | 北京九强生物技术股份有限公司 | 胱抑素c测定试剂盒 |
| CA2735590A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9421330B2 (en) * | 2008-11-03 | 2016-08-23 | Bayer Healthcare Llc | Mitigation of contrast-induced nephropathy |
| EP2364370B1 (en) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| US20100273207A1 (en) | 2009-04-24 | 2010-10-28 | Raymond Langley | Methods for Diagnosis of Sepsis and Risk of Death |
| WO2010126146A1 (ja) | 2009-04-30 | 2010-11-04 | Tanaka Noriaki | 腎疾患重篤度を判定する方法又は装置若しくはその作動方法 |
| EP2440214A4 (en) * | 2009-06-08 | 2013-07-31 | Quark Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES |
| US8709816B2 (en) | 2009-09-04 | 2014-04-29 | Tohoku University | Human renal disease marker substance |
| MX342967B (es) | 2009-12-20 | 2016-10-19 | Astute Medical Inc | Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. |
| WO2011146683A1 (en) | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| JP5899213B2 (ja) | 2010-08-06 | 2016-04-06 | マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ | 腎機能不全のバイオマーカーとしてのパールカン |
| JP5916058B2 (ja) | 2011-08-26 | 2016-05-11 | 国立大学法人東北大学 | 細胞ストレス状態のバイオマーカー |
| CA2845117A1 (en) | 2011-09-14 | 2013-03-21 | Basf Se | Means and methods for assessing kidney toxicity |
| WO2013048344A1 (en) * | 2011-09-29 | 2013-04-04 | National University Of Singapore | Urinary metabolomic markers for renal insufficiency |
| EP3410115A1 (en) * | 2013-05-14 | 2018-12-05 | Metabolon, Inc. | Tryptophan as a biomarkers for kidney function and methods using the same |
| US10865183B2 (en) * | 2016-07-28 | 2020-12-15 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
-
2014
- 2014-05-13 EP EP18183240.3A patent/EP3410115A1/en not_active Withdrawn
- 2014-05-13 WO PCT/US2014/037762 patent/WO2014186311A1/en not_active Ceased
- 2014-05-13 BR BR112015028253A patent/BR112015028253A2/pt not_active Application Discontinuation
- 2014-05-13 US US14/889,930 patent/US10539575B2/en active Active
- 2014-05-13 CA CA3184836A patent/CA3184836A1/en active Pending
- 2014-05-13 CN CN201910484069.9A patent/CN110196335A/zh active Pending
- 2014-05-13 AU AU2014265669A patent/AU2014265669B2/en active Active
- 2014-05-13 MX MX2015015561A patent/MX365061B/es active IP Right Grant
- 2014-05-13 JP JP2016514016A patent/JP6595984B2/ja active Active
- 2014-05-13 CN CN201480027332.7A patent/CN105209909B/zh active Active
- 2014-05-13 ES ES19176215T patent/ES2871823T3/es active Active
- 2014-05-13 ES ES14797070T patent/ES2702123T3/es active Active
- 2014-05-13 CA CA2911204A patent/CA2911204C/en active Active
- 2014-05-13 EP EP14797070.1A patent/EP2997366B1/en active Active
- 2014-05-13 EP EP19176215.2A patent/EP3546940B1/en active Active
- 2014-05-13 MX MX2019005748A patent/MX391220B/es unknown
-
2019
- 2019-12-02 US US16/700,098 patent/US20200103417A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1218331A1 (zh) | 2017-02-10 |
| EP2997366A4 (en) | 2017-04-12 |
| EP3410115A1 (en) | 2018-12-05 |
| AU2014265669A1 (en) | 2015-12-24 |
| ES2871823T3 (es) | 2021-11-02 |
| WO2014186311A1 (en) | 2014-11-20 |
| JP6595984B2 (ja) | 2019-10-23 |
| EP3546940A1 (en) | 2019-10-02 |
| CA2911204C (en) | 2023-03-28 |
| US20200103417A1 (en) | 2020-04-02 |
| BR112015028253A2 (pt) | 2017-07-25 |
| HK1222905A1 (en) | 2017-07-14 |
| CN110196335A (zh) | 2019-09-03 |
| CA2911204A1 (en) | 2014-11-20 |
| US10539575B2 (en) | 2020-01-21 |
| EP2997366A1 (en) | 2016-03-23 |
| MX391220B (es) | 2025-03-21 |
| CN105209909A (zh) | 2015-12-30 |
| EP2997366B1 (en) | 2018-10-10 |
| MX2019005748A (es) | 2019-08-12 |
| EP3546940B1 (en) | 2021-02-17 |
| US20160116486A1 (en) | 2016-04-28 |
| ES2702123T3 (es) | 2019-02-27 |
| AU2014265669B2 (en) | 2020-05-14 |
| JP2016520192A (ja) | 2016-07-11 |
| CN105209909B (zh) | 2019-06-07 |
| MX365061B (es) | 2019-05-22 |
| MX2015015561A (es) | 2016-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200103417A1 (en) | Biomarkers related to kidney function and methods using the same | |
| US20240019417A1 (en) | Methods and Systems for Determining Autism Spectrum Disorder Risk | |
| EP3129909B1 (en) | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | |
| Zhang et al. | Metabolomics in diabetes | |
| US20240230622A9 (en) | Methods and Systems for Determining Autism Spectrum Disorder Risk | |
| US20170370954A1 (en) | Biomarkers for Fatty Liver Disease and Methods Using the Same | |
| AU2012347557A1 (en) | Biomarkers for kidney cancer and methods using the same | |
| WO2013188333A1 (en) | Biomarkers related to nephrotoxicity and methods using the same | |
| HK1222905B (en) | Biomarkers related to kidney function and methods using the same | |
| US20180252706A1 (en) | Novel biomarkers for diagnosis and progression of primary progressive multiple sclerosis (ppms) | |
| HK40065445A (en) | Methods and systems for determining autism spectrum disorder risk | |
| HK40049279A (en) | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | |
| HK1218331B (en) | Biomarkers related to kidney function and methods using the same | |
| CA2875331A1 (en) | Methods for diagnosing chronic valvular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221221 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251031 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251231 |